We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Identification of Malignant Pancreatic Cysts May Lower Cancer Risk

By HospiMedica International staff writers
Posted on 25 Jun 2010
A new study has identified candidate biomarkers for the diagnosis of pancreatic cystic neoplasms, helping clinicians predict whether the cysts are benign or are precursors to invasive cancer. More...


Researchers at the University of Michigan (Ann Arbor, USA), Indiana University (Purdue, USA), and the Van Andel Research Institute (VARI, Grand Rapids, MI, USA) used a novel antibody-lectin sandwich microarray method to measure the protein expression and glycosylation of mucin (MUC)1, MUC5AC, MUC16, carcinoembryonic antigen, and other proteins implicated in pancreatic neoplasia in cyst fluid samples. A total of 53 cyst fluid samples were obtained from patients with mucinous cystic neoplasms, intraductal papillary mucinous neoplasms, serous cystadenomas, or pseudocysts, with confirmation of histologic diagnosis at surgical resection.

The results showed that the detection of a glycan variant on MUC5AC discriminated mucin-producing cystic tumors (mucinous cystic neoplasms and intraductal papillary mucinous neoplasms) from benign cystic lesions (serous cystadenomas and pseudocysts) with 78% sensitivity at 80% specificity; when used in combination with cyst fluid CA 19-9, the results were even higher, with a sensitivity of 87% at 86% specificity. The researchers also reported that the biomarkers performed better than cyst fluid carcinoembryonic antigen. The study was published in the May 2010 issue of Annals of Surgery.

"Because of the difficulty in detecting pancreatic cancer in its early stages, most cancers are advanced at the time of diagnosis and recur after removal of the tumor,” said lead author Brian Haab, Ph.D., a senior scientific investigator at VARI. "These results demonstrate the value of glycan variants for biomarker discovery and suggest that these biomarkers could greatly enhance the accuracy of differentiating pancreatic cystic tumors.”

The most common and deadly form of pancreatic cancer, pancreatic ductal adenocarcinomas, develops from three types of cysts. Moreover, although the most prevalent type is too small to be detected visually, cystic lesions of the pancreas are increasingly being recognized due to widespread use of high-resolution abdominal imaging. This situation presents an opportunity to intervene prior to malignant progression; however, effective implementation of this strategy has so far been hampered by difficulties in clearly distinguishing between cystic lesions with no malignant potential and those with malignant potential.

Related Links:

University of Michigan
Indiana University
Van Andel Research Institute



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Monitor/Defibrillator
Zenix
New
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.